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 25 
ABSTRACT   26 
To examine the contribution of Non-Esterified Fatty-Acids (NEFA) and incretin to insulin-27 
resistance and diabetes amelioration after malabsorptive metabolic-surgery that induces steatorrhea. 28 
In fact, NEFA infusion reduces glucose-stimulated insulin secretion and high-fat diets predict 29 
diabetes development. Six healthy-controls, 11 obese and 10 Type-2-Diabetic (T2D) subjects were 30 
studied before and 1 month after Bilio-Pancreatic Diversion (BPD). Twenty-four hours plasma 31 
glucose, NEFA, insulin, C-peptide, glucagon-like peptide-1 (GLP1) and gastric-inhibitory-32 
polypeptide (GIP) time courses were obtained and analyzed by Granger causality and graph 33 
analyses. Insulin sensitivity and secretion were computed by the oral glucose minimal-model. 34 
Before metabolic-surgery NEFA had the strongest influence on the other variables in both obese 35 
and T2D subjects. After surgery, GLP1 and C-peptide controlled the system in obese and T2D 36 
subjects. Twenty-four hours GIP levels were markedly reduced after BPD. Finally, GLP1 played a 37 
central role, but also insulin and C-peptide had a comparable relevance in the network of healthy 38 
controls. After BPD insulin sensitivity was completely normalized in both obese and T2D 39 
individuals. Increased 24-hours GLP1 circulating levels positively influence glucose homeostasis in 40 
both obese and T2D subjects who underwent a malabsorptive bariatric operation. In these latter, the 41 
reduction of plasma GIP also contributed to the improvement of glucose metabolism. It is possible 42 
that the combination of a pharmaceutical treatment reducing GIP and increasing GLP1 plasma 43 
levels will contribute to a better glycemic control in T2D. The application of Granger causality and 44 
graph-analyses shed new light on the patho-physiology of metabolic surgery. 45 
 46 
 47 
 48 
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INTRODUCTION 49 
Obesity and type 2 diabetes (T2D) are strictly associated. At least 285 million people worldwide are 50 
affected by diabetes and this number is expected to raise to 438 million by 2030 (21). In the United 51 
States, more than 1 in 3 adults are obese and 1 in 20 adults are morbidly obese (34).  52 
Together with a reduced physical activity, an excessive caloric intake represents a major 53 
driver of the global epidemics of obesity and type 2 diabetes. A large body of literature has shown 54 
that in experimental animals a high fat diet, particularly if rich in saturated fat, determines insulin 55 
resistance. Assessing the association between diet and T2D development over a 12-year time frame, 56 
van Dam et al. (50) found that consumption of a high fat diet and high intake of saturated fat are 57 
associated with the risk of increased diabetes. However, this significance disappeared when 58 
adjusting for the Body Mass Index (BMI), meaning that obesity was a stronger predictor of T2D.  59 
Prolonged non-esterified fatty acids (NEFA) infusion reduces glucose-stimulated insulin secretion 60 
and the disposition index (28). In addition, a raise in plasma NEFA leads to reduced insulin 61 
clearance (6, 7). 62 
Although lifestyle modifications successfully reduce the incidence of diabetes in high risk 63 
populations (49, 25), the compliance in the long term is poor (18). Metabolic surgery is an effective 64 
approach for the treatment of both obesity and T2D (12, 41, 31). However, its mechanism of action 65 
remains to be elucidated. In fact, the rapid resolution of diabetes and insulin resistance before any 66 
significant change in body weight challenge the weight loss as the only mechanistic effect (47, 36, 67 
17).  68 
Bilio-pancreatic diversion (BPD) is a type of metabolic operation associated with a massive 69 
lipid malabsorption and, consequently, with a dramatic circulating lipid lowering (30) and diabetes 70 
remission (31). It is, therefore, possible that the daily reduction of NEFA can be associated with the 71 
lowering of glucose circulating levels; alternatively 24 hour changes in glucagon-like peptide 1 72 
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(GLP1) and/or gastric inhibitory polypeptide (GIP) might drive the improvement of glucose control 73 
following BPD.  74 
In this study, we apply for the first time the Graph theory approach associated with Granger 75 
causality test to time series of metabolites and hormones in order to assess the interactions among 76 
hormones (insulin, C-peptide, GLP1 and GIP) and energy substrates, such as glucose and NEFA, as 77 
well as their directions.   78 
  79 
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MATERIALS AND METHODS 80 
 81 
We studied 11 obese subjects (4 women and 7 men, age 42.8 ± 2.6 y) with normal glucose 82 
tolerance, 10 obese subjects with type-2 diabetes (2 women and 8 men, 43.2 ± 2.4 y) and 6 healthy 83 
controls (4 women and 2 men, 43.1 ± 2.3 y). The anthropometric characteristic of the subjects are 84 
reported in Table 1. The study protocol was approved by the Ethical Committee of the Catholic 85 
University of Rome. All participants provided written
 
informed consent to participate in the study. 86 
Additional written
 
informed consent was obtained prior to the surgical procedures. 87 
Bilio-Pancreatic Diversion 88 
BPD (42, 29) consists of a ∼60% distal gastric resection with stapled closure of the 89 
duodenal stump. The residual volume of the stomach is ∼300 ml. The small bowel is transected at 90 
2.5 m from the ileo-cecal valve, and its distal end is anastomosed to the remaining stomach. The 91 
proximal end of the ileum, comprising the remaining small bowel carrying the bilio-pancreatic juice 92 
and excluded from food transit, is anastomosed in an end-to-side fashion to the bowel 50 cm 93 
proximal to the ileo-cecal valve. Consequently, the total length of absorbing bowel is brought to 94 
250 cm, the final 50 cm of which, the so-called common channel, represents the site where ingested 95 
food and bilio-pancreatic juices mix. 96 
Body composition 97 
Total body composition was determined by dual-energy x-ray absorptiometry using a Lunar 98 
Prodigy whole-body scanner (GE Medical Systems, Madison, WI). The subjects were scanned in 99 
light clothing lying flat on their backs and with arms by their side. Fat mass (FM) and fat free mass 100 
(FFM) were obtained in kg.  101 
 102 
Twenty-four–hour studies 103 
6 
 
All participants underwent the metabolic study at baseline and at 1 month after BPD, 104 
spending 24 h (starting at 08:00 hours) on a metabolic ward. During this period, 4 meals were 105 
administered. 106 
The patients received a total daily energy intake of 30 kcal (16.9% of energy as protein, 107 
34.6% fat and 48.5% carbohydrates) per kgFFM distributed as 14% at breakfast (09:00 hours), 36% at 108 
lunch (12:00–13:00 hours), 16% as an afternoon snack (16:00–16:30 hours) and 34% at dinner 109 
(19:00–20:00 hours). The food given and returned was weighed to the nearest gram on precision 110 
scales (KS-01; Rowenta, Berlin, Germany). Blood samples were drawn every 60 min from a central 111 
venous catheter for the measurement of glucose, NEFA, insulin, C-peptide, GLP1 and GIP 112 
concentrations. 113 
Analytical methods 114 
 115 
Plasma samples were immediately centrifuged and stored at −80°C before analyses. Plasma 116 
glucose was measured by the glucose oxidase method (Beckman, Fullerton, CA). Plasma insulin 117 
was assayed by microparticle enzyme immunoassay (Abbott, Pasadena, CA) with a sensitivity of 1 118 
μU/mL and an intra-assay CV of 6.6%. C-peptide was assayed by RIA (MYRIA; Technogenetics, 119 
Milan, Italy) as follows: a minimal detectable concentration, 17 pmol/L, and inter- and intra-assay 120 
CVs of 3.3–5.7% and 4.6 –5.3%, respectively. 121 
NEFA levels were determined using a colorimetric assay (HR Series NEFA-HR; Wako 122 
Diagnostics, Richmond, VA). For incretin analysis, venous blood was collected in ice-chilled 123 
EDTA dipotassium–treated tubes containing aprotinin (500 kallikrein inhibitory units per milliliter 124 
of blood), and then stored at −80°C. Immunoreactive GIP levels were determined using 0.1 mL 125 
plasma in a human GIP RIA kit (Peninsula Laboratories, Belmont, California). Intra-assay CV was 126 
6% and interassay CV was 8 and 12% for 20 and 80 pmol/L standards, respectively. Total GLP1 127 
was measured by RIA (Linco Research); intraassay and interassay CVs were 9–14% and 11–20%, 128 
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respectively. This assay has 100% specificity for GLP1 (7–36), GLP1 (9 –36), and GLP1 (7–37) 129 
and does not cross-react with glucagon (0.2%), GLP2 (<0.01%), or exendin (<0.01%). 130 
Mathematical Models 131 
Granger causality 132 
Wiener–Granger causality (“G-causality”) is a statistical notion of causality (16) applicable 133 
to time series data, based on predictability and precedence. A variable Y that evolves over time is 134 
said to G-cause another evolving variable X if the past of Y contains information that helps to 135 
predict the future of X over and above the information already contained in the past of X. In this 136 
predictive interpretation the G-causality between two variables, Y and X, may be written as FYX, 137 
which represents quantitatively the “degree to which the past of Y helps predict X, over and above 138 
the degree to which X is already predicted by its own past” (2). 139 
The X component at time t, Xt , is assumed to depend on the past of Y according to the 140 
equation (autoregressive model): 141 
𝑋𝑡 = ∑ 𝐴𝑥𝑥,𝑘 ∙ 𝑋𝑡−𝑘 +
𝑝
𝑘=1
∑ 𝐴𝑥𝑦,𝑘 ∙ 𝑌𝑡−𝑘 + 𝜀𝑥,𝑡
𝑝
𝑘=1
 , (1) 
where 𝑋 and 𝑌 are, in general, random vectors, 𝐴𝑥𝑥,𝑘 and 𝐴𝑥𝑦,𝑘 are matrices, 𝜀 is a noise term 142 
(regression residuals), and p is the model order. In particular, there is no conditional dependence of 143 
X on the past of Y (reduced regression) if  144 
Axy,1 = Axy,2 = · · · = Axy,p = 0. 145 
Therefore, technically, the G-causality is a test statistic for the null hypothesis of zero causality: 146 
H0: Axy,1 = Axy,2 = · · · = Axy,p = 0,          (2) 147 
and the null hypothesis will be rejected if the inclusion of the Y-term in Eq. (1) substantially 148 
improves the fitting capacity of the model. 149 
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In the presence of multivariate processes with variables X, Y and Z, where Z is an 150 
exogenous variable that affects X and Y, the full and reduced regressions for the X component are 151 
represented as: 152 
𝑋𝑡 = ∑ 𝐴𝑥𝑥,𝑘 ∙ 𝑋𝑡−𝑘 +
𝑝
𝑘=1
∑ 𝐴𝑥𝑦,𝑘 ∙ 𝑌𝑡−𝑘 + ∑ 𝐴𝑥𝑧,𝑘 ∙ 𝑍𝑡−𝑘 + 𝜀𝑥,𝑡        (3) 
𝑝
𝑘=1
𝑝
𝑘=1
 
and, with the null hypothesis in Eq. (2), we have     153 
𝑋𝑡 = ∑ 𝐴𝑥𝑥,𝑘
′ ∙ 𝑋𝑡−𝑘 +
𝑝
𝑘=1
∑ 𝐴𝑥𝑧,𝑘
′ ∙ 𝑍𝑡−𝑘 + 𝑥,𝑡
 ′  .        (4) 
𝑝
𝑘=1
 
According to Eqs. (3) and (4), the G-causality from Y to X, FYX|Z, is defined as 154 
𝐹𝑌 𝑋|𝑍 = ln
|𝑥𝑥
 ′  |
|𝑥𝑥|
 ,         (5) 
where 𝑥𝑥 = cov(𝜀𝑥,𝑡),  𝑥𝑥
′ = cov(𝑥,𝑡
 ′ ), and |  | denotes the determinant of the enclosed matrix. 155 
The determinants in the numerator and the denominator in the right-hand-side of Eq. (5) are a 156 
measure of the prediction error of the model in Eq. (4) and, respectively, of the model in Eq. (3). 157 
The quantity in Eq. (5) thus measures the improvement in model fitting when the past of Y variable 158 
is included in the model for X.  159 
As the conditioning variable Z is present in both Eqs. (3) and (4), the confounding effect of 160 
Z on the assessment of G-causality for X and Y can be eliminated. Thus, the method allows for the 161 
conditioning out of common causal influences and FYX|Z may be read as “the degree to which the 162 
past of Y helps predict X, over and above the degree to which X is already predicted by its own past 163 
and the past of Z”, see ref. (2).  However, in the presence of dependencies on exogenous inputs that 164 
are not measured, as it occurs in this study because the meals directly affect glucose and NEFA 165 
concentrations, the complete elimination of the confounding effects of these inputs on the 166 
assessment of G-causality cannot be achieved. The quantities F of the type reported in Eq. (5) may 167 
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be considered as a weighted directed graph linking the vertexes X, Y and Z, and we can thus obtain 168 
a (G-)causal graph. 169 
In summary, the type of analysis described above tries to establish whether the previous 170 
values of a time-changing variable Y, in our case the concentration of a metabolite or 171 
hormone, improve the prediction of another variable X compared to the prediction of X based only 172 
on its own previous values (equations (1) and (3)). This method so extends the usual notion of 173 
correlation to the stronger notion of G-causality (improved predictability of X, given the precedent 174 
values of Y). The procedure, which also holds for three or more variables, does not require 175 
assumptions about the biochemical and physiological processes involved nor to forrmulate a model 176 
that explicitly shows how the observed data are generated. 177 
For calculating the multivariate Granger causality (MVGC) from the time series data of 178 
glucose, NEFA, insulin, C-peptide, GLP1 and GIP concentrations, we used the MVGC Matlab 179 
Toolbox implemented by Barnett and Seth (2). The experimental data were interpolated every 20 180 
minutes using a cubic polynomial function to increase the number of time points and improve the 181 
reliability of the analysis. The order p of the model was assessed by the Akaike Information 182 
Criterion, which provides a balance between the goodness of fit of the model to data and the 183 
number of parameters to be estimated.  184 
Graph indexes  185 
The aim of the centrality measures in network analysis is that of determining the relative 186 
importance of a vertex within the graph (4). In our study, we consider two measures of centrality, 187 
degree and betweenness, and two measures typical of the network: density and efficiency. 188 
In degree is the sum of the weights of the edges going into a node and the out degree is the 189 
sum of the weights of the edges coming out of a node. The degree of each node is the sum of its in 190 
degree and out degree. Betweenness centrality measures the extent to which a vertex lies on paths 191 
between other vertices and it is, thus, an indicator of a node's centrality in the network. 192 
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Density is the sum of the weights of the edges in the graph, divided by the number of all 193 
possible edges. Efficiency of a graph is a measure of how efficiently it exchanges information.  For 194 
a weighted graph, it is defined as the sum of the minimum path lengths between variables, in 195 
proportion to the maximum efficiency of a comparable graph comprising all possible connections 196 
between variables. 197 
The standard errors of these measures were evaluated, for each group of subjects (obese, 198 
diabetic and control) by the Bootstrap method (52). 199 
Insulin sensitivity and secretion models 200 
The oral glucose minimal model (9) was used to compute the insulin sensitivity (SI) and the 201 
glucose effectiveness (SG). We used the glucose, insulin, and C-peptide values at fasting and after 202 
the breakfast to make calculations. The indexes of β-cell sensitivity to glucose, i.e. the dynamic β-203 
cell sensitivity, Φd, the static sensitivity, Φs, and the total sensitivity, Φ, were computed by the C-204 
peptide minimal model as proposed by Breda et al. (5). The model parameters were estimated by 205 
minimization of a weighted least-squares index using an active-set optimization algorithm of the 206 
MATLAB library. The coefficients of variation of the estimates were found to be <20%. We 207 
validated the oral glucose minimal model in a previous study (40) by comparison with the 208 
euglycemic hyperinsulinemic clamp, which is considered the golden standard for insulin sensitivity 209 
quantification. 210 
Robustness analysis 211 
 The robustness of the results was tested by two methods. First, we used the Bootstrap 212 
method. For each group of subjects, the resultant adjacency matrixes and the mean of the variable 213 
total degrees were computed. Second, we perturbed the time courses of the variables by an additive, 214 
zero-mean Gaussian noise. The SD of the noise was set proportional to the unperturbed value with 215 
multiplicative coefficients 0.001, 0.002, 0.005 and 0.01.The resultant adjacency matrixes and total 216 
degrees were computed. 217 
11 
 
Statistics 218 
All of the data are expressed as mean±SEM unless otherwise specified. The Wilcoxon 219 
paired-sample test and Mann-Whitney test, followed by Bonferroni correction, were used for 220 
intragroup and intergroup comparisons, respectively. The Student’s t-test was used to compare the 221 
graph indexes. Two-sided P<0.05 was considered significant. 222 
  223 
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RESULTS 224 
Weight and body composition 225 
The anthropometric data are summarized in Table 1. The patients lost a significant amount 226 
of weight after BPD. The weight loss was much more pronounced in obese subjects with normal 227 
glucose tolerance than in T2D patients. All patients lost both lean and fat mass, although the effect 228 
of bariatric surgery was stronger on fat mass reduction.  229 
Glycated hemoglobin was significantly improved after BPD, in particular in T2D patients. 230 
Hormonal and glucose and NEFA time courses 231 
Figure 1 reports the time courses of plasma glucose, NEFA, C-peptide, insulin, GLP1 and 232 
GIP concentrations in obese normoglycemic patients before and after BPD (A), in obese T2D 233 
patients before and after BPD (B), and in both controls and patients after gastro-intestinal surgery 234 
(C).  235 
Granger causality 236 
Before the graph analysis, we have implemented the Granger causality model to find the 237 
time-lagged causal connectivity among the time-series available. The model order was 10 for obese 238 
and diabetic subjects and 8 for controls. In this way, we have obtained the weighted adjacency 239 
matrix that gives the most probable, non-trivial, weights of the edges joining pairs of vertices in the 240 
graph (Figure 2, left column). Adjacencies are all nonzero only in controls. 241 
Graph analysis 242 
In the networks reported in Figure 2 (right column), the time-series variables represent the 243 
nodes and the significant connections obtained using the Granger correlations are the weighted 244 
edges. The value of the betweenness of a node is indicated by a color. The dominant variable/s have 245 
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a red color. As soon as the dominance of betweenness becomes less strong, the color is lighter, from 246 
orange to yellow. Some of the hedges are unidirectional, as also shown by the adjacency matrixes. 247 
In the obese subjects before bariatric surgery NEFA have the strongest influence on the 248 
other variables while, after surgery, GLP1 and C-peptide, i.e., the insulin secretion, play a central 249 
role. Also in the obese diabetic subjects, NEFA dominates over the other variables, but after 250 
bariatric surgery, GLP1 controls the system. In the healthy controls, finally, NEFA, GLP1 and C-251 
peptide have a comparable relevance in the network. 252 
Table 2 reports the numerical values of the betweenness (also shown by the color code in 253 
Figure 2, right column), of the in degrees, out degrees, as well as the total degrees of the network 254 
for plasma glucose, NEFA, insulin, C-peptide, GLP1 and GIP in obese and T2D subjects before and 255 
after surgery, and in control subjects. The values of the in degrees in Table 2 equal the sum (divided 256 
by 5, i.e. the maximal number of edges reaching a node) of the elements in the corresponding rows 257 
of the weighted adjacency matrix of Figure 2. Glucose in degree, for instance, is the sum (divided 258 
by 5) of entries of the first row of adjacency matrix, as seen from the numerical values shown in 259 
Figure 1 of the Appendix. Similarly, the values of out degrees equal the sum of elements in the 260 
corresponding columns of the weighted adjacency matrix. After surgery, the betweenness of all 261 
variables changes significantly, or tends to change, in the same direction in both obese and diabetic 262 
subjects (for instance, downwards in NEFA and upwards in GLP1). The betweenness of all 263 
variables does not differ significantly between controls and obese subjects post BPD, while, in 264 
diabetic subjects, the betweenness of GLP1 remains significantly lower than that of controls. 265 
In obese subjects, the in degrees increase significantly for C-peptide, GLP1 and GIP while 266 
decrease for glucose and insulin; the out degrees diminish only for NEFA and insulin, and raise 267 
only for GIP. No significant differences occur between obese post BPD and controls. Total degrees 268 
significantly increase post BPD for C-peptide, GLP1 and GIP. On the contrary, they decrease for 269 
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glucose, NEFA and insulin. However, the total degrees of insulin and GLP1 remain lower 270 
compared with those of controls. 271 
In diabetic subjects, the in degrees decrease for insulin and C-peptide and increase for 272 
GLP1, the out degrees lower for glucose, insulin and C-peptide and heighten for NEFA and GLP1; 273 
the out  degrees of NEFA are still significantly different from those of controls. Total degrees of 274 
NEFA and GLP1 increase post BPD. Conversely, total degrees of glucose and insulin decrease after 275 
surgery. Only the insulin and GIP degrees remain significantly lower compared with controls. 276 
Although the changes of degrees after surgery do not present a clear-cut pattern, in both 277 
obese and diabetic subjects the total degrees decrease in glucose and insulin, and increase in GLP1. 278 
The graph density significantly increases after surgery in the obese subjects (Student’s t-279 
test=8.32, P<0.001) and the graph efficiency increases (t=5.64, P<0.001). In T2D subjects, graph 280 
efficiency significantly increases (t=7.62, P<0.001) post BPD, while the graph density remains 281 
unchanged. The graph efficiency in obese and diabetic subjects post BPD is similar to the efficiency 282 
in controls (P=NS). Conversely, the graph density in controls remains higher than the density in 283 
obese and diabetic subjects after surgery (t=4.05 P<0.005 and t=4.06 P<0.005, respectively). 284 
Insulin sensitivity and secretion 285 
Table 1 reports SI, SG and cumulative insulin secretion (AUCISR).  286 
Insulin sensitivity increases more than 5 times in obese and 4 times in T2D subjects after 287 
BPD, matching the values observed in healthy controls. The cumulative insulin secretion decreases 288 
significantly in T2D subjects after BPD and even halves in obese subjects. 289 
Robustness analysis 290 
The adjacency matrixes computed by the Bootstrap method were marginally changed with 291 
respect to those shown in Fig. 2. The degrees computed by this method were not significantly 292 
different from those reported in Table 2.  When the Granger analysis was applied to the time-course 293 
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of the variables perturbed by noise the total degrees tended to decrease, but the difference of total 294 
degrees from before to after BPD remained rather stable as shown in the Figure 2 of the Appendix, 295 
so the changes from before to after BPD reflect substantially those in Table 2.  296 
  297 
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DISCUSSION 298 
 299 
In his study, we set up a graphical approach that models, identifies and visualizes the causal 300 
relationships between the components of data recorded during a 24-hour multi-meal test. Glucose, 301 
insulin, C-peptide, NEFA, GLP-1 and GIP concentrations were measured in T2D and in obese 302 
normoglycemic subjects, before and after malabsorptive metabolic surgery, and in healthy controls. 303 
Data were analyzed by the Granger causality method and graph analysis, which are widely 304 
used for instance in exploring multivariate time series of economic data (8) and brain networks (11). 305 
Our analysis permitted to establish the degree of association among the metabolic and hormonal 306 
time-series in a manner that allows identification of the network of strongest associations. The 307 
magnitude of the combined associations is measured by two indexes that are related to certain 308 
concepts of graph theory, i.e. the density of nodes and the efficiency of the network. These indexes 309 
are used to identify the degree of interaction among the variables and they provide a quantitative 310 
basis for grouping energy substrates and hormones. 311 
The Granger and graph methods do not require a model that describes the underlying 312 
physiology of the glucose-insulin system, and use all the recorded data simultaneously to reveal the 313 
mutual influences among the variables recorded. Therefore, it may capture features in response to 314 
the meals that are hardly detectable by a particular mathematical model. 315 
Limitations of our study are that Granger causality is a statistical inference on the 316 
relationships among variables but do not necessarily imply physical causality which needs to be 317 
determined by an interventional experiment. However, the introduction of causality rules, as in the 318 
Granger causality, may provide a means to distinguish whether any of our variables interact directly 319 
or whether the appearance of a correlation is a result of chance or the variables are forced by a 320 
common third variable. Another limitation is the lack of data on glucagon concentrations, which is a 321 
major player in type 2 diabetes with GIP increasing glucagon circulating levels in type 2 diabetes 322 
(43). Finally, we stress that the use of splines to  interpolate our hourly data might bias the analysis. 323 
Rapidly occurring phenomena, such as the early phase of insulin response after initiating a meal, 324 
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may indeed be missed because of the spline approximation that produces a smoothing in the time-325 
course of the variables 326 
To investigate a complex system such as that of the in vivo glucose metabolic control as a 327 
whole, it is important to study how hormones and energy substrates are connected. The components 328 
of the glucose system and their interactions are best characterized as a network, and they are 329 
conveniently represented as a graph where nodes are connected with edges. 330 
Our analysis shows that NEFA is the most strongly connected variable in the network 331 
system of both obese and diabetic subjects at the baseline. Plasma NEFA are produced by the 332 
hydrolysis of triglycerides (TG) stored in the adipose tissue, however after a meal dietary TG are 333 
hydrolyzed in the circulatory stream by lipoprotein lipase (LPL) and the proportion escaping in the 334 
so-called spillover process joins the plasma NEFA pool (14). In insulin resistant individuals, fat 335 
mobilization is not efficiently suppressed by insulin. NEFA concentrations are associated acutely 336 
with insulin resistance reducing insulin-mediated glucose uptake (3, 44), increasing hepatic 337 
gluconeogenesis (38, 45) and reducing hepatic insulin clearance (51). 338 
BPD is a mainly malabsorptive metabolic operation that greatly reduces lipid absorption 339 
and, thus, its action in improving insulin sensitivity might depend on the reduction of circulating 340 
levels of NEFA. However, here we show that it is the increase in GLP1 plasma levels, rather than 341 
the reduction of NEFA circulating levels, which drives the reduction of plasma glucose and insulin 342 
over 24 hours. Rather than finding a reduction of plasma NEFA we found unchanged or sometime 343 
slightly increased levels. Fasting and low energy intake are associated with increased circulating 344 
levels of NEFA. In fact, the highest plasma NEFA concentrations are observed after an overnight 345 
fast, with suppression after each meal (37, 27, 39). During energy deprivation, adipose tissue 346 
lipolysis is increased with generation of fatty acids and glycerol, which are released into the 347 
circulatory stream for use by other organs as energy substrates. Food deprivation in rats is 348 
associated with doubled hormone sensitive lipase protein expression and activity in the adipose 349 
18 
 
tissue (46). After bariatric surgery it was reported that all lipids in tissues and plasma diminished 350 
except plasma NEFA, which maintained higher levels than controls (35). Therefore, NEFA plasma 351 
levels remained elevated after bariatric surgery due to energy intake restriction and weight loss.  352 
In addition, the high plasma levels of GIP observed in T2D subjects at baseline were 353 
detrimental for their glucose metabolism. GIP signaling, in fact, promotes fat accumulation in 354 
experimental animals (19, 22, 23, 24, 26, 33). Obese humans also hyper-secrete GIP (10, 13) 355 
suggesting that GIP may promote obesity in humans. GIP receptor knockout rodents are protected 356 
from obesity-related diabetes (32), as well animals genetically engineered to lack K cells also resist 357 
development of high fat diet-induced obesity and insulin resistance without any collateral serious 358 
adverse effect (1). Furthermore, chronic administration of (Pro
3
GIP),  a specific and stable GIP 359 
receptor antagonist, can prevent or reverse many of the established metabolic alterations, including 360 
insulin resistance, observed in type 2 diabetes (15). 361 
In the present study, both T2D and normoglycemic obese patients had the normalization of 362 
insulin resistance just 1 month after BPD. In addition, glycated hemoglobin was drastically reduced 363 
after BPD in T2D patients (Table 1). Likewise, a very low calorie diet administered to T2D patients 364 
for 1 month was effective in improving glycated hemoglobin (20). 365 
In conclusion, increased GLP1 circulating levels over 24 hours positively impact on glucose 366 
homeostasis in both obese and obese diabetic individuals who underwent a malabsorptive operation. 367 
The reduction of plasma GIP also contributed to the improvement of glucose metabolism. It is 368 
possible that the combination of a pharmaceutical treatment reducing GIP and increasing GLP1 369 
plasma levels will contribute to a better glycemic control in type 2 diabetes. Indeed, recent findings 370 
(48) show that an approach based on triple hormone therapy (GLP1, peptide YY and 371 
oxyntomodulin) is likely to be a useful tool against obesity.  372 
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The application of Granger causality and graph analyses shed new light on the patho-373 
physiology of gastro-intestinal surgery and on glycemic control, and it opens a new avenue to the 374 
use of these computational techniques in metabolic studies. 375 
  376 
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Figure legends 557 
 558 
Figure 1 559 
Time course of plasma glucose, insulin, C-peptide, GLP1, NEFA and GIP concentrations in obese 560 
patients at baseline (black lines) and at 1 month after BPD (red lines) (panel A), in diabetic patients 561 
at baseline (black) and at 1 month after BPD (red) (panel B), and in both controls (black bold lines) 562 
and surgical patients (blue for obese and green for diabetic subjects) at 1 month after BPD (panel 563 
C). The vertical lines indicate the meal times. Concentration values are mean ± SE.  564 
 565 
Figure 2 566 
Adjacency matrixes (left column) and betweenness centrality indexes (right column) of the graphs 567 
in obese and diabetic patients pre and post BPD and in control subjects. The numbers from 1 to 6 568 
indicate plasma glucose, NEFA, insulin, C-peptide, GLP1 and GIP, respectively. The colors, from 569 
yellow for lowest value to red for highest value, represent the values of the variables (weighted 570 
adjacency in the matrixes and betweenness in the nodes of the graph). Note that the color scale is 571 
different in the various panels. 572 
 573 
  574 
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Table 1. Anthropometric and metabolic parameters of controls and of the obese and diabetic 575 
patients at baseline and at 1 month after BPD. 576 
Significances: 
*
 indicates a significant difference (P<0.05) between variables in controls vs. patients 577 
post BPD, and 
#
 indicates a significant difference (P<0.05) between variables in patients before and 578 
after BPD. 579 
 580 
 581 
 582 
  583 
 
Parameters 
  
Obese subjects 
pre BPD 
Obese subjects 
post BPD 
Diabetic 
subjects 
pre BPD 
Diabetic 
subjects 
post BPD 
Controls 
Weight 
kg 
131.10 ± 7.79 118.05 ± 7.91
#,*
 134.60  ± 8.15 124.42 ± 9.14
#*
 72.10 ± 2.66 
BMI 
kg
 
m
-2
 
46.77 ± 2.29 42.15 ± 2.47
#,*
 45.29  ± 2.23 41.56 ± 2.59
#*
 26.46 ± 0.49 
FFM 
kg 
70.89 ± 4.71 67.31 ± 5.66
*
 76.60  ± 6.97 74.12 ± 6.87
#* 
50.68 ± 4.25 
FM 
kg 
60.19 ± 4.29 50.73 ± 3.91
#,*
 59.20  ± 5.27 53.64 ± 0.56
#*
 21.42 ± 2.18 
HbA1c 
% 
5.98 ± 0.31 5.00 ± 0.45
#
 11.88 ± 1.53
*
 7.71 ± 0.74
#*
 5.04 ± 0.36 
SG×10
2 
min
-1
 
4.20  ± 0.26 3.81 ± 0.16 2.96  ± 0.49 3.84 ± 0.44 3.74±0.21 
SI×10
4 
min
-1
pM
-1
 
 0.317 ± 0.06
 
 1.70 ± 0.27
#
 0.322 ± 0.09 1.28 ± 0.18
#
 1.44±0.23 
AUCISR 
nmol 
42.83±8.30
 
 21.05±5.21
#
 29.67±6.3
#
 23.59±7.9 20.45±2.76 
Φs×10
9
 
min
-1
 
25.3±6.59
 
  43.35±6.21
#
 12.81±3.16 40.9±6.35
#
 35.7±5.9 
Φd×10
9
 
 
739.96±202.71 
 
383.81±106.25
#
 684.45±216.93 525.46±155.46 401.6±108.7 
Φ×109 
min
-1
 
33.91±6.1 47.7±10.1
#
 20.9±3.43 46.6±6.51
#
 40.7±5.8 
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Table 2. Graph theory and network analysis of the interactions among glucose, NEFA, insulin, C-584 
peptide, GIP and GLP1 (mean ± SD). 585 
Significances: * post BPD vs pre BPD P<0.05, ° post BPD vs controls P<0.05. 586 
Obese 
subjects 
Glucose NEFA Insulin C-peptide GLP1 GIP 
Betweenness 
pre 
0.21±0.14 0.78±0.14 0.35±0.14 0.06±0.07 0.24±0.14 0.80±0.21 
Betweenness 
post 
0.32±0.14 0.03±0.07* 0.50±0.21 0.19±0.07* 0.39±0.14* 0.24±0.07* 
In degree pre 0.095±0.009 0.069±0.010 0.062±0.010 0.043±0.012 0.079±0.010 0.062±0.013 
In degree 
post 
0.052±0.008* 0.065±0.009 0.033±0.008* 0.081±0.022* 0.145±0.015* 0.110±0.018* 
Out degree 
pre 
0.051±0.009 0.097±0.008 0.071±0.013 0.060±0.008 0.069±0.011 0.063±0.007 
Out degree 
post 
0.058±0.013 0.064±0.008* 0.057±0.010* 0.055±0.016 0.076±0.011 0.178±0.011* 
Degree pre 0.146±0.015 0.167±0.012 0.133±0.018 0.103±0.018 0.148±0.016 0.125±0.015 
Degree post 0.110±0.017*° 0.130±0.014* 0.089±0.016*° 0.136±0.035* 0.221±0.021*° 0.288±0.025* 
 
Diabetic 
subjects  
 
Glucose NEFA Insulin C-peptide GLP1 GIP 
Betweenness 
pre  
0.12±0.28 0.73±0.21    0.03±0.07     0.12±0.14     0.06±0.07     0.18±0.14 
Betweenness 
post 
0.24±0.21     0.01±0.07*     0.13±0.14*     0.21±0.21     0.14±0.14*°     0.13±0.14 
In degree pre 0.066±0.017 0.151±0.023 0.115±0.017 0.109±0.009 0.085±0.009 0.088±0.017 
In degree 
post 
0.079±0.010* 0.149±0.028 0.077±0.013* 0.070±0.015* 0.136±0.019* 0.083±0.018 
Out degree 
pre 
0.108±0.014 0.075±0.014 0.113±0.008 0.114±0.016 0.112±0.016 0.091±0.012 
Out degree  
post 
0.058±0.015* 0.172±0.014*° 0.063±0.017* 0.079±0.020* 0.138±0.016* 0.084±0.020 
Degree pre 0.175±0.028 0.226±0.034 0.228±0.018 0.223±0.015 0.197±0.019 0.179±0.023 
Degree post 0.137±0.017* 0.321±0.034* 0.140±0.023*° 0.150±0.032* 0.274±0.029* 0.166±0.032° 
 
Controls  
 
Glucose NEFA Insulin C-peptide GLP1 GIP 
Betweenness  
0.45±0.14     0.07±0.14     0.15±0.14     0.13±0.14     0.59±0.14     0.06±0.07 
In degree  0.095±0.031 0.110±0.038 0.112±0.037 0.071±0.026 0.169±0.015 0.111±0.020 
Out degree  0.115±0.026 0.077±0.034 0.107±0.027 0.104±0.018 0.144±0.025 0.120±0.023 
Degree 0.210±0.043 0.187±0.048 0.219±0.037 0.175± 0.038 0.313±0.023 0.231±0.027 
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